Part B Insider - 2003 Issue 32
Drug Cuts: Oncologists Face Steep Drug Cuts, But Will Practice Expenses Compensate?
Subscribe or sign in to view the full article.
Article Overview
This article explains how a new Medicare reform bill changes drug payment methodology over time and examines related payment issues for oncology practices. It covers broad updates to drug pricing, competitive acquisition demonstrations, practice expense valuation for drug administration, and HHS review of billing and reporting policies. The piece is relevant to oncologists, medical coders, billing staff, and practice administrators following Medicare reimbursement policy.
Why This Topic Matters
The article focuses on payment and reporting changes that can affect oncology reimbursement, practice operations, and compliance planning under Medicare.
What You Will Learn
- How Medicare drug payment methodology is changing over time
- Why oncology practice expense valuation is being reexamined
- What kinds of HHS reviews are being discussed for drug administration reporting
- How competitive acquisition demonstrations may affect physician drug supply arrangements
Who Should Read This
- Oncologists
- Medical coders
- Billing specialists
- Practice administrators
- Healthcare compliance staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com